20 Participants NeededMy employer runs this trial

Poly-L-Lactic Acid for Pelvic Organ Prolapse

CK
DU
Overseen ByDuke Urogynecology Clinical Research Coordinators

What You Need to Know Before You Apply

What is the purpose of this trial?

Pelvic organ prolapse (POP) is a condition characterized by descent of vaginal walls, uterus and cervix, or the perineum and causes a sensation of vaginal bulge and pelvic pressure. Millions of women in the United States are affected, and the number is expected to rise significantly in the coming decades. Current treatments either involve conservative measures or surgery. Surgery may lead to changes in vaginal topography and scar tissue, both of which impact sexual function. There are no treatment options that restore vaginal tissue strength and preserve, even optimize, sensation and blood flow to the vagina. This project will evaluate the use of poly-L-lactic acid (PLLA), an FDA-approved biostimulant for dermatologic use with an expansive safety profile over the past decade, in the treatment of anterior wall POP and its impact on sexual function. Our study will compare intravaginal injection of PLLA vs. placebo in women with stage 2 cystocele and investigate safety and preliminary efficacy of PLLA. Prior study of regenerative biologics for the vulva and vagina have shown great promise, but use of these has not been explored for POP. This randomized controlled trial has the potential to shift the paradigm of prolapse management from surgical reconstruction to regeneration. This shift will prevent the risks of surgery and has the potential to improve sexual function and quality of life by resolving POP.

Who Is on the Research Team?

CK

Cassandra Kisby, MD MS FACOG FACS

Principal Investigator

Duke University

Are You a Good Fit for This Trial?

Inclusion Criteria

* Positive response to PFDI-20 question 3: Do you usually have a bulge or something falling out that you can see or feel in the vaginal area?
I am bothered by my symptoms, even if only a little.
I am abstinent, using birth control, or postmenopausal.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive three injections of PLLA or placebo, one per month, in the tissues of the front wall of the vagina

3 months
3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including adverse events and pelvic organ prolapse quantification

6 months
Multiple visits (in-person) at 1, 2, 6, and 9 months

What Are the Treatments Tested in This Trial?

Interventions

  • Poly-L-Lactic Acid

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: PLLA (Sculptra) InjectionExperimental Treatment1 Intervention
Group II: Control InjectionPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cassandra Kisby

Lead Sponsor

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Collaborator

Trials
508
Recruited
1,090,000+